Chapter 15. Coronavirus Disease-2019 (COVID-19)-Positive Patients as Susceptible Hosts to Severe Fungal Coinfections


Heloisa Freire Frota1,2, Carolline Margot Albanez Lorentino1, Luca Mokus dos Santos1, Marcos Vinicius Santos1, Nahyara Louize Miranda Siqueira1, Maryam Roudbary3, Lucimar Ferreira Kneipp4,5, Marta Helena Branquinha1,5 and André Luis Souza dos Santos1,2,5
1Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
2Programa de Pós-Graduação em Bioquímica, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
3Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4Laboratório de Taxonomia, Bioquímica e Bioprospecção de Fungos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
5Rede Micologia RJ – Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Rio de Janeiro, Brazil

Part of the book: The Book of Fungal Pathogens


Since the World Health Organization (WHO) declared the pandemic of coronavirus disease-2019 (COVID-19) on March 11th, 2020, the world has faced a health crisis that includes challenges such as its diagnosis, treatment and prevention, resulting in more than 595 million confirmed cases worldwide and more than 6.4 million deaths (August 25th, 2022). The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to the suppression of the immune system, particularly due to the storm of inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-6, IL-2 and IL-1) and the reduction of anti-inflammatory cells (e.g., CD4+ and CD8+ T lymphocytes). These factors, when associated with the use of steroids, prolonged stay in the intensive care unit (ICU), older age, diabetes, cardiovascular and pulmonary diseases as well as inherited and acquired immunodeficiency, contribute to the colonization of other infectious agents, such as respiratory viruses, gram-positive and gram-negative bacteria, yeasts and filamentous fungi. The incidence of opportunistic fungal infections has increased significantly in patients with COVID-19, especially in individuals with critical medical conditions and presenting comorbidities, such as the ones cited above. The main fungal agents causing coinfections in these particular patients are Aspergillus spp., Candida spp. and fungi belonging to the order Mucorales. The similarity of clinical symptoms between COVID[1]19 and fungal infections, such as fever, dry cough, dyspnea, myalgia and headache, makes it harder to get a conclusive laboratory identification and diagnosis, which represents a challenge for treatment. To worsen this bad scenario, the available antifungals are substantially limited and some fungal species are intrinsically resistant to classical chemotherapeutic drugs used in the clinical settings. In parallel, the antifungals can also present drug interactions besides serious and severe side effects, such as hepatotoxicity and nephrotoxicity, which can greatly aggravate the patients’ clinical condition. All these facts highlight the urgent need for early diagnosis of the fungal pathogens for the proper choice of antifungal treatment in order to combat these relevant yet still neglected diseases on a global scale. The present chapter focused on summarizing the main fungal infections reported in COVID-19-positive patients.

Keywords: COVID-19, fungal infections, SARS-CoV-2, coinfections


[1] Lin, Y., Hu, Z., Zhao, Q., Alias, H., Danaee, M., Wong, L. P., (2020). Understanding COVID-19
vaccine demand and hesitancy: A nationwide online survey in China. PLoS. Negl. Trop. Dis. 14(12),
[2] World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. 2022 [February 11].
Available from:
[3] Giovanetti, M., Benedetti, F., Campisi, G., Ciccozzi, A., Fabris, S., Ceccarelli, G., Tambone, V.,
Caruso, A., Angeletti, S., Zella, D., Ciccozzi, M., (2020). Evolution patterns of SARS-CoV-2: Snapshot
on its genome variants. Biochem. Biophys. Res. Commun. 29, 88-91.
[4] Meyerowitz, E. A., Richterman, A., Gandhi, R. T., Sax, P. E., (2021). Transmission of SARS-CoV-2:
A review of viral, host, and environmental factors. Ann. Intern. Med. 174(1), 69-79.
[5] Li, Z. Y., Meng, L. Y., (2020). [The prevention and control of a new coronavirus infection in
department of stomatology]. Zhonghua Kou Qiang Yi Xue Za Zhi. 55, 217-222.
[6] Majumder, J., Minko, T., (2021). Recent developments on therapeutic and diagnostic approaches for
COVID-19. AAPS J. 23(1), 14.
[7] Rai, P., Kumar, B. K., Deekshit, V. K., Karunasagar, I., Karunasagar, I., (2021). Detection technologies
and recent developments in the diagnosis of COVID-19 infection. Appl. Microbiol.
Biotechnol. 105, 441-455.
[8] Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., Ciu, L., (2020). Co-infection
with respiratory pathogens among COVID-2019 cases. Virus Res. (285), 198005.
[9] Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Raskshit, P., Singh, S., Abraham,
P., Panda, S., Team, N., (2021). SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in
the second wave of COVID-19 in Maharashtra, India. Microorganisms. 9, 1542.
[10] Qin, S., Cui, M., Sun, S., Zhou, J., Du, Z., Cui, Y., (2021). Genome characterization and potential risk
assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529). Zoonoses. 1, 13.
[11] Silva, L. N., Mello, T. P., Ramos, L. S., Branquinha, M. H., Roudbary, M., Santos, A. L. S., (2020).
Fungal infections in COVID-19-positive patients: A lack of optimal treatment options. Curr. Top. Med.
Chem. 20, 1951-1957.
[12] Salehi, M., Ahmadikia, K., Mahmoudi, S., (2020). Oropharyngeal candidiasis in hospitalised COVID 19 patients from Iran: species identification and antifungal susceptibility pattern. Mycoses. 63(8), 771-778.
[13] Manda, D., Sen, I., Thakral, P., Das, S. S., Virupakshapp, C. B., Malik, D., (2022). Invasive fungal
infection in COVID-19-recovered patient detected on 18F-FDG-labeled leukocytes PET/CT scan. Clin.
Nucl. Med. 47, 177-179.
[14] Soni, S., Pudake, R. N., Jain, U., Chauhan, N., (2022). A systematic review on SARS-CoV-2-associated
fungal coinfections. J. Med. Virol. 94, 99-109.
[15] Pemán, J., Ruiz-Gaitán, A., García-Vidal, C., Salavert, M., Ramírez, P., Puchades, F., García-Hita, M.,
Alastruey-Izquierdo, A., Quidós, G., (2020). Fungal co-infection in COVID-19 patients: Should we be
concerned? Rev. Iberoam. Micol. 37, 41-46.
[16] Lansbury, L., Lim, B., Baskaran, V., Lim, W. S., (2020). Co-infections in people with COVID-19: a
systematic review and meta-analysis. J. Infect. 81, 266-275.
[17] Richardson, M. D., Warnock, D. W. (2003). Fungal infection: diagnosis and Management (3th
edition). Oxford, Blackwell Publishing Ltd.
[18] Borman, A. M., Palmer, M. D., Fraser, M., Patterson, Z., Mann, C., Oliver, D., Linton, C. J., Gough,
M., Brown, P., Dzietczyk, A., Hedley, M., McLachlan, S., King, J., Johnson, E. M., (2020). COVID 19-associated
invasive aspergillosis: Data from the UK National Mycology Reference Laboratory. J.
Clin. Microbiol. 59(1), 1-12.
[19] Brown, G. D., Denning, D. W., Levitz, S. M., (2012). Tackling human fungal infections.
Science. 336, 647.
[20] Kosmidis, C., Denning, D. W., (2015). The clinical spectrum of pulmonary aspergillosis. Thorax.
70(3), 270-277.
[21] Sisodia, J., Bajaj, T. (2021). Allergic bronchopulmonary aspergillosis. Treasure Island, StatPearls
Publishing LLC.
[22] Jenks, J. D., Hoenigl, M., (2018). Treatment of aspergillosis. J. Fungi. 4(3), 98.
[23] Dellière, S., Dudoignon, E., Fodil, S., Voicu, S., Collet, M., Oillic, P. A., Salmona, M., Dépret, F.,
Ghelfenstein-Ferreira, T., Plaud, B., Chousterman, B., Bretagne, S., Azoulay, E., Mebazaa, A.,
Megarbane, B., Alanio, A., (2020). Risk factors associated with COVID-19-associated pulmonary
aspergillosis in ICU patients: a French multicentric retrospective cohort.
Clin. Microbiol. Infect. 27(5), 790-790.
[24] Rajic, J., Gmizic, I., Gunjak, T., Milosevic, V., Pantic, N., Sabljic, N., Mitrovic, M., Stefanovic, A. D.,
Lazic, L., Jovanovic, S., Milosevic, I., Barac, A., Vidovic, A., (2021). COVID-19-associated
pulmonary aspergillosis in patients with acute leukemia: A single-center study. J. Fungi. 7(11), 890.
[25] Sivasubramanian, G., Ghanem, H., Maison-Fomotar, M., Jain, R, Libke, R., (2021). COVID-19-
associated pulmonary aspergillosis: a single-center experience in Central Valley, California. J. Fungi.
7(11), 948.
[26] Schein, F., Munoz-Pons, H., Mahinc, C., Grange, R., Cathébras, P., Flori, P., (2020). Fatal aspergillosis
complicating severe SARS-CoV-2 infection: A case report. J. Mycol. Med. 30(4), 101039.
[27] Mohamed, A., Hassan., T., Trzos-Grzybowska, M, Thomas, J, Quinn, A, O’Sullivan, M., Griffin, A.,
Rogers, T. R., Talento, A. F., (2020). Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2
co-infection: a lethal combination. Med. Mycol. Case Rep. 31, 11-14.
[28] Wasylyshyn, A. I., Wasylyshyn, G. R., Linder, K. A., Miceli, M. H., (2021). COVID-19-associated
pulmonary aspergillosis at an academic medical center in the Midwestern United States.
Mycopathologia. 186(4), 499-505.
[29] Ranhel, D., Ribeiro, A., Batista, J., Pessanha, M., Cristovam, E., Duarte, A., Dias, A., Coelho, L.,
Monteiro, F., Freire, P., Veríssimo, C., Sabino, R., Toscano, C., (2021). COVID-19-associated invasive
pulmonary aspergillosis in the intensive care unit: A case series in a Portuguese hospital, J. Fungi,
7(10), 881, 1-11.
[30] Fortarezza, F., Boscolo, A., Pezzuto, F., Lunardi, F., Jesús Acosta, M., Giraudo, C., Vecchio, C. D.,
Sella, N., Tiberio, I., Godi, I., Cattelan, A., Vedovelli, L., Gregori, D., Vettor, R., Viale, P., Navalesi,
P., Calabrese, F., (2021). Proven COVID-19-associated pulmonary aspergillosis in patients with severe
respiratory failure. Mycoses, 64(10), 1223–1229.
[31] Abolghasemi, S., Hakamifard, A., Sharifynia, S., Pourabdollah Toutkaboni, M., Azhdari Tehrani, H.,
(2021). Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to
Aspergillus terreus: A case study. Clin. Case Rep. 9(4), 2414–2418.
[32] Sharma, A., Hofmeyr, A., Bansal, A., Thakkar, D., Lam, L., Harrington, Z., Bhonagiri, D., (2021).
COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report. Med. Mycol.
Reports. 31, 6–10.
[33] Vélez Pintado, M., Camiro-Zúñiga, A., Aguilar Soto, M., Cuenca, D., Mercado, M., Crabtree-Ramirez,
B., (2021). COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico
City. Med. Mycol. 59(8), 828–833.
[34] Meijer, E., Dofferhoff, A., Hoiting, O., Meis, J. F., (2021). COVID-19-associated pulmonary
aspergillosis: a prospective single-center dual case series. Mycoses. 64(4), 457–464.
[35] Tio, S. Y., Williams, E., Worth, L. J., Deane, A. M., Bond, K., Slavin, M. A., Sasadeusz, J., (2021).
Invasive pulmonary aspergillosis in critically ill patients with COVID-19 in Australia: implications for
screening and treatment. Intern. Med. J. 51(12), 2129–2132.
[36] Hakamifard, A., Hashemi, M., Fakhim, H., Aboutalebian, S., Hajiahmadi, S., Mohammadi, R., (2021).
Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus
ochraceus. J. Mycol. Med. 31(2).
[37] Shadrivova, O., Gusev, D., Vashukova, M., Lobzin, D., Gusarov, V., Zamyatin, M., Zavrazhnov, A.,
Mitichkin, M., Borzona, Y., Kozlova, O., Desyatik, E., Burygina, E., Ignatyeva, S., Oganesyan, E.,
Vasilyeva, N., Klimko, N., Group, W., (2021). COVID-19-associated pulmonary aspergillosis in
Russia. J. Fungi. 7(12), 1059.
[38] Gregoire, E., Pirotte, B. F., Moerman, F., Altdorfer, A., Gaspard, L., Firre, E., Moonen, M., Fraipont,
V., Ernst, M., Darcis, G., (2021). Incidence and risk factors of COVID-19-associated pulmonary
aspergillosis in intensive care unit – a monocentric retrospective observational study. Pathogens.
10(11), 1370.
[39] Chumbita, M., Puerta-Alcalde, P., Garcia-Pouton, N., García-Vidal, C., (2021). COVID-19 and fungal
infections: Etiopathogenesis and therapeutic implications. Rev. Esp. Quimioter. 34, 72–75.
[40] Nasri, E., Shoaei, P., Vakili, B., Mirhendi, H., Sadeghi, S., Hajiahmadi, S., Sadeghi, A., Vaezi, A.,
Badali, H., Fakhim, H., (2020). Fatal invasive pulmonary aspergillosis in COVID-19 patient with acute
myeloid leukemia in Iran. Mycopathologia. 185(6), 1077–1084.
[41] Mitaka, H., Perlman, D. C., Javaid, W., Salomon, N., (2020). Putative invasive pulmonary aspergillosis
in critically ill patients with COVID-19: An observational study from New York City.
Mycoses. 63(12), 1368–1372.
[42] Savi, D., Valente, G., Iacovelli, A., Olmati, F., Bezzi, M., Palange, P., (2020). Uncommon presentation
of allergic bronchopulmonary aspergillosis during the COVID-19 lockdown: a case report. BMC Pulm
Med. 20(1), 325.
[43] Sánchez Martín, C., Madrid Martínez, E., González Pellicer, R., Armero Ibáñez, R., Martínez
González, E., Llau Pitarch, J. V., (2022). Aspergilosis pulmonar invasiva en pacientes con síndrome
de distrés respiratorio por COVID-19 [Invasive pulmonary aspergillosis in patients with acute
respiratory syndrome by COVID-19]. Rev. Esp. Anest. Rean. 69(1), 48–53.
[44] Imoto, W., Himura, H., Matsuo, K., Kawata, S., Kiritoshi, A., Deguchi, R., Miyashita, M, Kaga, S.,
Nodo, T., Yamamoto, K., Yamada, K., Uchida, K., Nishimura, T., Yamamoto, K., Mizobata, Y.,
Kakeya, H., (2021). COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report.
J. Infec Chemother. 27(6), 911–914.
[45] Casalini, G., Giacomelli, A., Ridolfo, A., Gervasoni, C., Antinori, S., (2021). Invasive fungal infections
complicating COVID-19: A narrative review. J. Fungi. 7(11), 921.
[46] Iwanaga, Y., Kawanami, T., Yamasaki, K., Sakakibara, H., Ikushima, I., Ikegami, H., Ikegami, H.,
Tahana, M., Akata, K., Mukae, H., Yatera, K., (2021). A fatal case of COVID-19-associated invasive
pulmonary aspergillosis. J. Infect. Chemother. 27(7), 1102–1107.
[47] Wiederhold, N. P., (2022). Emerging Fungal infections: New species, new names, and antifungal
resistance. Clinical Chemistry, 68(1), 83-90.
[48] Fuller, J., Dingle, T. C., Bull, A., Shokoples, S., Laverdière, M., Baxter, M. R., Adam, H. J., Karlowsky,
J. A., Zhanel, G. G., (2019). Species distribution and antifungal susceptibility of invasive Candida
isolates from Canadian hospitals: results of the CANWARD 2011–16 study. J. Antimicrob. Chemother.
74, 48-54.
[49] Shroff, D., Narula, R., Atri, N., Chakravarti, A., Gandhi, A., Sapra, N., Bhatia, G., Pawar, S. R., Narain,
S., (2021). Endogenous fungal endophthalmitis following intensive corticosteroid therapy in severe
COVID-19 disease. Indian J. Ophthalmol. 69(7), 1909-1914.
[50] Bhotla, H. K., Balasubramanian, B., Meyyazhagan, A., Pushparaj, K., Easwaran, M., Pappusamy, M.,
Robert, A. A., Arumugam, V. A., Tsibizova, V., Alfalih, A. M., Aljowaie, R. M., Saravanan, M.,
Renzo, G. C., (2021). Opportunistic mycoses in COVID-19 patients/survivors: Epidemic inside a
pandemic. J. Infect. Public Health. 14(11), 1720-1726.
[51] Roudbary, M., Kumar, S., Kumar, A., Černáková, L., Nikoomanesh, F., Rodrigues, C. F., (2021).
Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID 19 patients. J. Fungi. 7(9), 720.
[52] Keighley, C., Chen, S. C., Marriott, D., Pope, A., Chapman, B., Kennedy, K., Bak, N., Wilson, H. L.,
McDonald, K., Darvall, j., Halliday, C., Kidd, S., Nguyen, O., Hajkowicz, K., Sorrel, T. C., Van Hal,
S., Slavin, A., (2019). Candidaemia and a risk predictive model for overall mortality: a prospective
multicentre study. BMC Infect. Dis. 19(1), 1-10.
[53] Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., Azeredo, J., (2012). Candida
glabrata, Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and
antifungal resistance. FEMS Microb. Rev. 36(2), 288-305.
[54] Cuevaez-Gonzalez, M. V., Espinosa-Cristóbal, L. F., Donohue-Cornejo, A., Tovar-Carrillo, K. L.,
Saucedo-Acuña, R. A., García-Calderón, A. G., Guzmán-Gastelum, D. A., Cuevas-Gonzalez, J. C.,
(2021). COVID-19 and its manifestations in the oral cavity:
A systematic review. Medicine. 100(51), e28327.
[55] Goyal, M., Murthy, S. I., Annum, S., (2021). Retinal manifestations in patients following COVID-19
infection: A consecutive case series. Indian Journal Ophthalm. 69(5), 1275.
[56] Alataby, H., Atemnkeng, F., Bains, S. S., Kenne, F. M., Diaz, K., Nfonoyim, J., (2020). A COVID-19
case complicated by Candida dubliniensis and Klebsiella pneumoniae-carbapenem-resistant
Enterobacteriaceae. J. Med. Cases. 11(12), 403.
[57] Nucci, M., Barreiros, G., Guimarães, L. F., Deriquehem, V. A., Castiñeiras, A. C., Nouér, S. A., (2021).
Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic.
Mycoses. 64(2), 152-156.
[58] Tafti, D., Kluckman, M., Dearborn, M. C., Hunninghake, J., Clayton, S., (2020). COVID-19 in patients
with hematologic-oncologic risk factors: Complications in three patients. Cureus. 12(12), e12064.
[59] Gorospe-Sarasúa, L., Gallego-Rivera, J. I., Muñoz-Molina, G. M., Mirambeaux-Villalona, R. M.,
Ajuria-Illarramendi, O., González-García, A., Barbolla-Díaz, I., (2020). [Delayed Candida
costochondritis and spondylitis in a post-COVID-19 patient previously treated with corticosteroids,
antibiotics, and tocilizumab]. Arch. Bronconeumol. 57, 48-50.
[60] Segrelles-Calvo, G., de S Araújo, G. R., Llopis-Pastor, E., Carrillo, J., Hernández-Hernández, M., Rey,
L., Melean, N. R., Escribano, I., Antón, E., Zamarro, C., García-Salmones, M., Frases, S., (2021).
Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and
associated risk factors. Respir. Med. 188, 106619.
[61] Salehi, M., Ahmadikia, K., Mahmoudi, S., Kalantari, S., Jamalimoghadamsiahkali, S., Izadi, A.,
Mohammad, K., Manshadi, S. A. D., Seifi, A., Ghiasvand, F., Khajavirad, N., Ebrahimi, S., Koohfar,
A., Boekhout, T., Khodavaisy, S., (2020). Oropharyngeal candidiasis in hospitalised COVID-19
patients from Iran: Species identification and antifungal susceptibility pattern.
Mycoses. 63(8), 771-778.
[62] Davoodi, L., Faeli, L., Mirzakhani, R., Jalalian, R., Shokohi, T., Kermani, F., (2021). Catastrophic
Candida prosthetic valve endocarditis and COVID-19 comorbidity: A rare case. Curr. Med. Mycol.
7(2), 43.
[63] Chowdhary, A., Tarai, B., Singh, A., Sharma, A., (2020). Multidrug-resistant Candida auris infections
in critically ill coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis. 26(11), 2694.
[64] Prestel, C., Anderson, E., Forsberg, K., Lyman, M., de Perio, M. A., Kuhar, D., Edwards, K., Rivera,
M., Shugart, A., Walters, M., Dotson, N., (2021). Candida auris outbreak in a COVID-19 specialty
care unit—Florida, July–August 2020. Morb. Mort Weekly Report. 70(2), 56.
[65] Moin, S., Farooqi, J., Rattani, S., Nasir, N., Zaka, S., Jabeen, K., (2021). C. auris and non-C. auris
candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan.
Med Mycol. 59(12), 1238-1242.
[66] Mahmoud, H. K. A., Aburahma, M. A., Elkhawaga, M. Z., El-Mokhtar, A. A., Sayed, M. A., Medhat,
M. A., (2020). Predictors of severity and co-infection resistance profile in COVID-19 patients: first
report from upper Egypt. Infect. Drug Resist. 13, 3409-3422.
[67] Awada, B., Alam, W., Chalfoun, M., Araj, G., Bizri, A. R., (2021). COVID-19 and Candida
duobushaemulonii superinfection: A case report. J. Mycol. Med. 31(3), 101168.
[68] Seitz, T., Hoepler, W., Weseslindtner, L., Aberle, J. H., Aberle, S. W., Puchhammer-Stoeckl, E.,
Baumgartner, S., Traugott, M., Karolyi, M., Pawelka, E., Niculescu, L., Friese, E., Neuhold, S., Stahl,
D., Madl, C., Zoufaly, A., Wenisch, C., Laferl, H., (2020). Successful management of the first reported
case in Austria of COVID-19 with ARDS. Infection. 48(4), 647-651.
[69] Posteraro, B., Torelli, R., Vella, A., Leone, P. M., De Angelis, G., De Carolis, E., Ventura, G.,
Sanguinetti, M., Fantoni, M., (2020). Pan-echinocandin-resistant Candida glabrata bloodstream
infection complicating COVID-19: A fatal case report. J. Fungi. 6(3), 163.
[70] Abdelhadi, A., Kassem, A., (2021). Candida pneumonia with lung abscess as a complication of severe
COVID-19 pneumonia. Int. Med Case Rep J. 14, 853-861.
[71] Gorospe-Sarasúa, L., Gallego-Rivera, J. I., Muñoz-Molina, G. M., Mirambeaux-Villalona, R. M.,
Ajuria-Illarramendi, O., González-García, A., Barbolla-Díaz (2021). Delayed Candida costochondritis
and spondylitis in a Post-COVID-19 patient previously treated with corticosteroids, antibiotics, and
tocilizumab. Arch. Bronconeumol. 57, 48-50.
[72] Goravey, W., Ali, G. A., Ali, M., Ibrahim, E. B., Al Maslamani, M., Hadi, H. A., (2021). Ominous
combination: COVID-19 disease and Candida auris fungemia—Case report and review of the
literature. Clin. Case Report. 9(9).
[73] Ohashi, N., Ideta, Y., Takeda, A., Iwai, T., Kioi, M., Miyazaki, A., Mitsudo, K., (2021). Oral
candidiasis caused by ciclesonide in a patient with COVID-19 pneumonia: A case report and literature
review. SAGE Open Med. Case Rep. 9, 2050313X211048279.
[74] Spiliopoulou, A., Kolonitsiou, F., Vrioni, G., Tsoupra, S., Lekkou, A., Paliogianni, F., (2021). Invasive
Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case
report and review of the literature. J. Mycol. Med. 32(2), 101236.
[75] Villanueva-Lozano, H., Treviño-Rangel, R. D. J., González, G. M., Ramírez-Elizondo, M. T., Lara Medrano, R., Aleman-Bocanegra, M. C., Guajardo-Lara, C. E., Gaona-Chávez, N., Castilleja-Leal, F.,
Torre-Amione, G., Martínez-Reséndez, M. F., (2021). Outbreak of Candida auris infection in a
COVID-19 hospital in Mexico. Clin. Microbiol Infect. 27(5), 813-816.
[76] Magnasco, L., Mikulska, M., Giacobbe, D. R., Taramasso, L., Vena, A., Dentone, C., Dettori, S.,
Tutino, S., Labate, L., Di Pilato, V., Crea, F., Coppo, E., Codda, G., Robba, C., Ball, L., Patroniti, N.,
Marchese, A., Pelosi, P., Bassetti, M., (2021). Spread of carbapenem-resistant Gram-negatives and
Candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial
stewardship? Microorganisms, 9(1), 95.
[77] Miranda, M. A., Sousa, S. C., Montes, V. L., (2021). Post-COVID-19 neurocandidiasis. Neurol. Sci.
42(11), 4419-4420.
[78] Arastehfar, A., Shaban, T., Zarrinfar, H., Roudbary, M., Ghazanfari, M., Hedayati, M. T., Sedaghat,
A., Ilkit, M., Najafzadeh, M. J., Perlin, D. S., (2021). Candidemia among iranian patients with severe
COVID-19 admitted to ICUs. J. Fungi. 7(4), 280.
[79] Almeida, J. N. D., Brandão, I. B., Francisco, E. C., de Almeida, S. L. R., de Oliveira Dias, P., Pereira,
F. M., (2021). Axillary Digital Thermometers uplifted a multidrug‐susceptible Candida auris outbreak
among COVID-19 patients in Brazil. Mycoses. 64(9), 1062-1072.
[80] Almeida, J. N. D., Francisco, E. C., Hagen, F., Brandão, I. B., Pereira, F. M., Presta Dias, P. H., Costa,
M. M. M., Jordão, R. T. S., Groot, T., Colombo, A. L., (2021). Emergence of Candida auris in Brazil
in a COVID-19 intensive care unit. J. Fungi. 7(3), 220.
[81] Bölükbaşı, Y., Genç, G. E., Orhun, G., Kuşkucu, M. A., Çağatay, A., Önel, M., Öngen, B., Agaçfidan,
A., Esen, F., Erturan, Z., (2021). First case of COVID-19 positive Candida auris fungemia in Turkey.
Mikrobiyol. Bul. 55(4), 648-655.
[82] Meawed, T. E., Ahmed, S. M., Mowafy, S. M., Samir, G. M., Anis, R. H., (2021). Bacterial and fungal
ventilator associated pneumonia in critically ill COVID-19 patients during the second wave. J. Infect.
Public Health. 14(10), 1375-1380.
[83] Bhagali, R., Prabhudesai, N. P., Prabhudesai, M. N. (2021). Post COVID-19 opportunistic Candida
retinitis: A case report. Indian J. Ophthalmol. 69(4), 987.
[84] Szabo, B. G., Lakatos, B., Bobek, I., Szabo, E., Szlavik, J., Vályi-Nagy, I., (2021). Invasive fungal
infections among critically ill adult COVID-19 patients: First experiences from the national centre in
Hungary. J. Med. Mycology. 31(4), 101198.
[85] Hanson, B. M., Dinh, A. Q., Tran, T. T., Arenas, S., Pronty, D., Gershengorn, H. B., Ferreira, T., Arias,
C. A., Shukla, B. S., (2021). Candida auris invasive infections during a COVID-19 case surge.
Antimicrob. Chemother. 65(10), e0114621.
[86] Brikman, S., Dori, G., Kasher, C., Yanovskay, A., Strauss, M., Colodner, R., Bisharat, N., Chazan, B.,
(2021). Candida bloodstream infection, a dire complication in hospitalized COVID-19 patients: Three
cases from a single center in Northern Israel. Isr. Med. Assoc. J. 23(10), 615-617.
[87] Sari, A. P., Darnindro, N., Yohanes, A., Mokoagow, M. I., (2021). Role of tocilizumab for concomitant
systemic fungal infection in severe COVID-19 patient: Case report. Medicine. 100(12), e25173.
[88] Moreno-Gómez, L. M., Esteban-Sinovas, O., García-Pérez, D., García-Posadas, G., Delgado Fernández, J., Paredes, I., (2021). Case report: SARS-CoV-2 infection – are we redeemed? A report of
Candida spondylodiscitis as a late complication. Front. Med. 8, 751101.
[89] Görkem, A., Hafize, S. A. V., Özge, K. A. A. N., Esma, E. R. E. N. (2021). Coronavirus disease and
candidemia infection: A case report. J. Mycol Med. 31(3), 101155.
[90] Allaw, F., Kara Zahreddine, N., Ibrahim, A., Tannous, J., Taleb, H., Bizri, A. R., Dbaibo, G., Kanj, S.
S., (2021). First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in
Lebanon. Pathogens. 10(2), 157.
[91] Bhogireddy, R., Krishnamurthy, V., Jabaris S. S. L., Pullaiah, C. P., Manohar, S., (2021). Is
Mucormycosis an inevitable complication of Covid-19 in India? Braz. J. Infect Dis. 25(3), 101597.
[92] Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., Kontoyiannis, D. P., (2012).
Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Diseas. 54, S23–S34.
[93] Mahalaxmi, I., Jayaramayya, K., Venkatesan, D., Subramaniam, M. D., Renu, K., Vijayakumar, P.,
Narayanasamy, A., Gopalakrishnan, A. V., Kumar, N. S., Sivaprakash, P., Rao, K. R. S. S., Vellingiri,
B., (2021). Mucormycosis: An opportunistic pathogen during COVID-19. Environ. Res. 201, 111643.
[94] Gupta N. K., Kapre M., Gupta H., Vaidya G. K., Jani S., Meshram S., Singh, S., Kapre, V., Ravi, R.,
Tambe, V., Thakkar, N., Mundhada, A., (2021). Risk based decision algorithms for management of
COVID-19 associated rhino-orbital mucormycosis. Indian J. Otolaryngol. Head Neck Surg. 30, 1-8.
[95] Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., Petrikkos, G., (2018). Challenges in
the diagnosis and treatment of mucormycosis. Med. Mycol. 56, 93–101.
[96] Lin, E., Moua, T., Limper, A. H., (2017). Pulmonary mucormycosis: clinical features and outcomes.
Infection. 45(4), 443–448.
[97] Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B.,
Hoenigl, M., Jensen, H., Lagrou, K., Lewis, R. E., Mellinghoff, S. C., Mer, M., Pana, Z. D. P., Seidel,
D., Sheppard, D. C., Wahba, R., Akova, M., Alanio, A., Al-Hatmi, A. M. S., Arikan-Akdagli, S.,
Badali, H., Ben-Ami, R., Bonifaz, A., Bretagne, S., Castagnola, E., Chayakulkeeree, M., Colombo, A.
L., Corzo-León, D. E., Drgona, L., Groll, A. H., Guinea, J., Heussel, C. P., Ibrahim, A. S., Kanj, S. S.,
Klimko, N., Lackner, M., Lamoth, F., Lanternier, F., Lass-Floerl, C., Lee, D. G., Lehrncher, T.,
Lmimoini, B. E., Mares, M., Maschmeyer, G., Meis, J. F., Meletiadis, J., Morrissey, C. O., Nucci, M.,
Oladele, R., Pagano, L., Pasqualotto, A., Patel, A., Racil, Z., Richardson, M., Roilides, E., Ruhnke, M.,
Seyedmousavi, S., Sidharthan, N., Singh, N., János, S., Skiada, A., Slavin, M., Soman, R., Spellberg,
B., Steinbach, W., Tan, B. H., Ullmann, A. J., Vehreschild, J. J., Vehreschild, M. J. G. T., Walsh, T.
J., White, P. L., Wiederhold, N. P., Zaoutis, T., Chakrabarti, A., (2019). Mucormycosis ECMM MSG
Global Guideline Writing Group. Global guideline for the diagnosis and management of
mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with
the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 19(12), 405-421.
[98] Selarka, L., Sharma, S., Saini, D., Sharma, S., Batra, A., Waghmare, V. T., Dileep, P., Patel, S., Shah,
M., Parikh, T., Darji, P., Patel, A., Goswami, G., Shah, A., Shah, S., Lathiya, H., Shah M., Sharma, P.,
Chopra, S., Gupta, A., Jain, N., Khan, E., Sharma, V. K., Sharma, A. K., Chan, A. C. Y., Ong, J. J. Y.,
(2021). Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 64(10),
[99] Kumar, M., Sarma, D. K., Shubham, S., Kumawat, M., Verma, V., Singh, B., Nagpal, R., Tiwari, R.
R., (2021). Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr. Res. Microb. Sci.
2, 100057.
[100] Werthman-Ehrenreich, A., (2021). Mucormycosis with orbital compartment syndrome in a patient with
COVID-19. Am. J. Emerg. Med. 42.
[101] Prasad, A., Mishra, M., Saha, K., (2021). Invasive mucormycosis – an enigma. Cureus. 13(12), 20475,
[102] Poorna, T. A., Joshna, E. K., John, B., Prakash, P., (2022). Palatal flap: An optimistic salvagable option
to negate the maxillectomy defects in COVID related rhino-orbito-cerebral mucormycosis. Indian J.
Otolaryngol. Head Neck Surg. 2022, 9:1-3.
[103] Jati, M., Koutsu, R., Nagarkar, N. M., (2022). Rhino-cerebral mucormycosis with otologic
involvement. Indian J. Otolaryngol. Head Neck Surg. 8, 1-4.
[104] Ravi, M. B., Srinivas, S., Silina, E., Sengupta, S., Tekwani, T., Achar, R. R., (2022). Prosthetic
rehabilitation of rhino orbital mucormycosis associated with COVID-19: A case series. Clin. Cosmet.
Investig. Dent. 2022, 6, 1-10.
[105] Ingle, Y., Sarode, S. C., Sarode, G., Ingle, M., Ingle, S., (2022). Concurrent plexiform ameloblastoma
and COVID-19-associated mucormycosis of the maxilla. Oral Oncol. 8, 125105712.
[106] Patnaik, A., Sharma, B., Ahmad, R., Kumar, A., Chitrotpala, R., Gupta, M., (2021). A case of bilateral
central retinal artery occlusion in a post-COVID rhino-orbital-cerebral mucormycosis patient. Cureus.
13(11), 20062.
[107] Melchers, M., Festen, B., Den Dekker, B. M., Mooren, E. R. M., Van Binsbergen, A. L., Van Bree, S.
H. W., Heusinkveld, M., Schellars, R., Buil, J. B., Verweij, P. E., Zanten, A. R. H., (2022). A 67-year old male patient with COVID-19 with worsening respiratory function and acute kidney failure. Chest.
161(1), 5-11.
[108] Vaddi, S. P., Khetavath, S. M., Babu, D. M., Maturu, N., Bhulaxmi, Swathi, Mohan, K., Prasad, D.,
Jawahar, B., Krv, R. R., (2021). Bilateral renal Mucor mycosis presenting as anuria in a COVIDS-19
recovered patient: A case report and review of literature. Urology. 161, 12-14.
[109] Pruthi, H., Muthu, V., Bhujade, H., Sharma, A., Baloji, A., Ratnakara, R. G., Bal, A., Singh, H.,
Sandhu, M. S., Negi, S., Chakrabarti, A., Singhal, M., (2021). Pulmonary artery pseudoaneurysm in
COVID-19-associated pulmonary mucormycosis: Case series and systematic review of the literature.
Mycopathologia. 22, 1–7.
[110] Chowdhury, M., Takata, J., Beegun, I., Burd, C., Tatla, T., Corrah, T., (2022). Image challenge: A
diabetic man with facial swelling following recent COVID-19 infection. Clin. Infect. Pract. 13,
[111] Yuvaraj, M., Mathapati, P. M., Seena, C. R., Ramaswami, S., (2021). Gastric mucormycosis with
splenic invasion a rare abdominal complication of COVID-19 pneumonia. J. Clin. Imaging. Sci. 17,
[112] Jain, S., Guttal, S. S., (2021). Prosthetic rehabilitation of nose after partial rhinectomy in a patient
affected with mucormycosis: A case report. Indian J. Otolaryngol. Head Neck Surg. 29, 1-4.
[113] Tambe, R. R., Hinduja, A., Sunil, S., Varaiya, A., Joshi, A., (2021). Cutaneous mucormycosis in a
patient of severe COVID-19 pneumonia: A rarer than rare case report. Indian J. Crit. Care Med. 25(11),
[114] Benhadid-Brahmi, Y., Hamane, S., Soyer, B., Mebazaa, A., Alanio, A., Chousterman, B., Bretagne, S.,
Dellière, S., (2021). COVID-19-associated mixed mold infection: A case report of aspergillosis and
mucormycosis and a literature review. J. Mycol. Med. 32(1), 101231.
[115] Torabiyan, S., Dalfardi, B., Sanjari, M., (2021). Asymptomatic COVID-19 as a risk factor of diabetic
ketoacidosis and mucormycosis: A case report and review of the literature. Case Rep. Endocrinol. 11,
[116] Abdoli, A., Falahi, S., Kenarkoohi, A., (2021). COVID-19-associated opportunistic infections: a
snapshot on the current reports. Clin. Exp. Med. 1-20.
[117] Heaney, A. K., Head, J. R., Broen, K., Click, K., Taylor, J., Balmes, J. R., Zelner, J., Remais, J., (2021).
Coccidioidomycosis and COVID-19 co-infection, United States, 2020. Emerg. Infect. Dis. 27(5), 1266-
[118] Frías-De-León, M. G., Pinto-Almazán, R., Hernández-Castro, R., García-Salazar, E., Meza-Meneses,
P., Rodríguez-Cerdeira, C., Arenas, R., Conde-Cuevas, E., Acosta-Altamirano, G., (2021).
Epidemiology of systemic mycoses in the COVID-19 pandemic. J. Fungi. 7(7), 556.
[119] Chang, C. C., Senining, R., Kim, J., Goyal, R., (2020). An acute pulmonary coccidioidomycosis
coinfection in a patient presenting with multifocal pneumonia with COVID-19. J. Investig. Med. High
Impact. Case Rep. 8.
[120] Nassif, E. F., Maloney, N., Conley, A. C., Keung, E. Z. (2021). Disseminated coccidioidomycosis
following COVID-19 mimicking metastatic thoracic relapse of well-differentiated liposarcoma: A case
report. Front. Med. (Lausanne). 8, 715939.
[121] Shah, A. S., Heidari, A., Civelli, V. F., Sharma, R., Chark, C. S., Munoz, A. D., Ragland, A. S.,
Johnson, R. H., (2020). The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: A case
report. J. Investig. Med. High Impact. Case Rep. 8, 1-4.
[122] Chen, J. C., Wong, D., Rabi, S., Worswick, S., DeClerck, B., Gibb, J. (2021). All That Coughs Is Not
COVID-19: A delayed diagnosis of disseminated coccidioidomycosis following severe acute
respiratory syndrome coronavirus 2 infection. Open Forum Infect. Dis. 8, 7.
[123] Krauth, D. S., Jamros, C. M., Rivard, S. C., Olson, N. H., Maves, R. C. (2021). Accelerated progression
of disseminated coccidioidomycosis following SARS-CoV-2 infection: A Case Report. Mil. Med. 186,
[124] Nielsen, M. C., Reynoso, D., Ren, P. (2021). The brief case: A fatal case of SARS-CoV-2 coinfection
with Coccidioides in Texas – another challenge we face. J. Clin. Microbiol. 59,8.
[125] Woldie, I. L., Brown, I. G., Nwadiaro, N. F., Patel, A., Jarrar, M., Quint, E., Khokhotva, V., Hugel, N.,
Winger, M., Briskin, A., (2020). Autoimmune hemolytic anemia in a 24-year-old patient with COVID 19 complicated by secondary cryptococcemia and acute necrotizing encephalitis: A case report and
review of literature. J. Med. Cases. 11(11), 362-365.
[126] Khatib, M., Ahmed, A. A., Shaat, S. B., Mohamed, A. S., Nashwan, A. J., (2021). Cryptococcemia in
a patient with COVID‐19: A case report. Clin. Case Rep. 9(2), 853-855.
[127] Passerini, M., Terzi, R., Piscaglia, M., Passerini, S., Piconi, S., (2020). Disseminated cryptococcosis in
a patient with metastatic prostate cancer who died in the coronavirus disease 2019 (COVID-19)
outbreak. Cureus. 12(5), e8254.
[128] Ghaneme, H., Sivasubramanian, G., (2021). Meningoencefalite por Cryptococcus neoformans em
paciente imunocompetente após infecção por COVID-19. Case Rep. Infect. Dis. 5597473.
[129] Passarelli, V., Perosa, A. H., Luna, L. K. S., Conte, D. D., Nascimento, O. A., Ota-Arakaki, J., Bellei,
N., (2020). Detected SARS-CoV-2 in ascitic fluid followed by cryptococcemia: A case report. SN
Compr. Clin. Med. 2(11), 2414-2418.
[130] Roudbary, M., Kumar, S., Kumar, A., Černáková, L., Nikoomanesh, F., Rodrigues, C., (2021).
Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID 19 patients. J. Fungi. 7(9), 720.
[131] Gonzalez, A. J. C., Montenegro-Idrogo, J. J., Vadillo, A. R. V., Torres, M. S., Matos, I. V., Delgado,
C. P. R., (2020). Hospital-acquired SARS-CoV-2 pneumonia in a person living with HIV. Int. J. STD
AIDS. 31(13), 1320-1322.
[132] Alegre-González, D., Herrera, S., Bernal, J., Soriano, A., Bodro, M., Disseminated Cryptococcus
neoformans infection associated to COVID-19. Med. Mycol. Case Rep. 34, 35-37.
[133] Traver, E. C., Sánchez, M. M., (2022). Pulmonary aspergillosis and cryptococcosis as a complication
of COVID-19. Med. Mycol. Case Rep. 35, 22-25.
[134] Gil, Y., Gil, Y., Markou, T., (2021). The emergence of cryptococcemia in COVID-19 infection: A case
report. Cureus. 13(11), e19761.
[135] Chastain, D. B., Henao-Martínez, A. F., Dykes, A. C., Steele, G. M., Stoudenmire, L. L., Thomas, G.
M., Kung, V., Franco-Paredes, C., (2022). Missed opportunities to identify cryptococcosis in COVID 19 patients: a case report and literature review. Ther. Adv. Infect. Dis. 9, 20499361211066363.
[136] Chong, W. H., Saha, B. K., Chopra, A., (2021). Narrative review of the relationship between COVID 19 and PJP: does it represent coinfection or colonization? Infection. 49(6),1079-1090.
[137] Gerber, V., Ruch, Y., Chamaraux-Tran, T.-N., Oulehri, W., Schneider, F., Lindner, V., Greigert, V.,
Denis, J., Brunet, J., Danion, F., (2021). Detection of Pneumocystis jirovecii in patients with severe
COVID-19: Diagnostic and therapeutic challenges. J. Fungi. 7, 585.
[138] Jeican, I. I., Inisca, P., Gheban, D., Tabaran, F., Aluas, M., Trombitas, V., Cristea, V., Crivii, C., Junie,
L. M., Albu, S., (2021). COVID-19 and Pneumocyst jirovecii pulmonary coinfection – The first case
confirmed through autopsy. Medicina. 57, 302.
[139] Coleman, H., Snell, L. B., Simons, R., Douthwaite, S. T., Lee, M. J., (2020). Coronavirus disease 2019
and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV. AIDS. 34, 1258-1260.
[140] Bhat, P., Noval, M., Doub, J. B., Heil, E., (2020). Concurrent COVID-19 and Pneumocystis jirovecii
pneumonia in a severely immunocompromised 25-year-old patient. Int. J. Infect. Dis. 99, 119-121.
[141] De Francesco, M. A., Alberici, F., Bossini, N., Scolari, F., Pascucci, F., Tomasoni, G., (2020).
Pneumocystis jirevocii and SARS-CoV-2 co-Infection: a common feature in transplant recipients?
Vaccines. 8, 544.
[142] Menon, A. A., Berg, D. D., Brea, E. J., Deutsch, A. J., Kidia, K. K., Thurber, E. G., (2020). A case of
COVID-19 and Pneumocystis jirovecii co-infection. Am. J. Respir. Crit. Care Med. 202(1), 136-138.
[143] Kelly, S., Waters, L., Cevik, M., Collins, S., Lewis, J., Wu, M.-S., (2020). Pneumocystis pneumonia,
a COVID-19 mimic, reminds us of the importance of HIV testing in COVID-19. Clin. Med. 20(6), 590-
[144] Mang, S., Kaddu-Mulindwa, D., Metz, C., Becker, A., Seiler, F., Smola, S., (2020). Pneumocystis
jirovecii pneumonia and severe acute respiratory syndrome coronavirus 2 coinfection in a patient with
newly diagnosed HIV-1 infection. Clin. Infect. Dis. 72, 1487-1489.
[145] Mouren, D., Goyard, C., Catherinot, E., Givel, C., Chabrol, A., Tcherakian, C., (2021). COVID-19 and
Pneumocystis jirovecii pneumonia: back to the basics. Respir. Med. Res. 79, 100814.
[146] Broadhurst, A. G. B., Lalla, U., Taljaard, J. J., Louw, E. H., Koegelenberg, C. F. N., Allwood, B. W.,
(2021). The diagnostic challenge of pneumocystis pneumonia and COVID-19 co-infection in HIV.
Respirol Case Rep. 9(4), e00725.
[147] Rubiano, C., Tompkins, K., Sellers, S. A., Bramson, B., Eron, J., Parr, J. B., (2021). Pneumocystis and
severe acute respiratory syndrome coronavirus 2 coinfection: a case report and review of an emerging
diagnostic dilemma. Open Forum Infect. Dis. 8, 633.
[148] Bertolini, M., Mutti, M. F., Barletta, J. A., Falak, A., Cuatz, D., Sisto, A., (2020). COVID-19 associated
with AIDS-related disseminated histoplasmosis: a case report. Int. J. STD AIDS. 31(12), 1222-1224.
[149] Messina, F. A., Marin, E., Caceres, D. H., Romero, M., Depardo, R., Priarone, M. M., (2020).
Coronavirus disease 2019 (COVID-19) in a patient with disseminated histoplasmosis and HIV – A case
report from Argentina and literature review. J. Fungi. 6(4), 275.
[150] Basso, R. P., Poester, V. R., Benelli, J. L., Stevens, D. A., Zogbi, H. E., Vasconcellos, I. C. D. S.,
(2021). COVID-19-associated histoplasmosis in an AIDS patient. Mycopathologia. 186(1), 109-112.
[151] Cronyn, V., Howard, J., Chiang, L., Le, L., Tims-Cook, Z., Gertz, A. M. (2021). Trichosporon asahii
urinary tract infection in a patient with severe COVID-19. Case Rep. Infect. Dis. 1-6.
[152] Ali, G. A., Husain, A., Salah, H., Goravey, W. (2021). Trichosporon asahii fungemia and COVID-19
co-infection: An emerging fungal pathogen; case report and review of the literature. IDCases. 25.
[153] Almeida, J. N., Moreno, L., Francisco, E. C., Marques, G. N., Mendes, A. V., Barberino, M G.,
Colombo, A. L., (2021). Trichosporon asahii superinfections in critically ill COVID-19 patients
overexposed to antimicrobials and corticosteroids. Mycoses. 64(8), 817-822.
[154] Samaddar, A., Diwakar, J. Krishnam, P., Kumari, H. B., Kavya, M., Konar, S., Sharma, D. A.,
Nandeesh, B. N., Goyal, A., Nagarathna, S., (2019). COVID-19-associated brain abscess caused by
Trichosporon dohaense: A case report and review of literature. Med. Mycol. Case Reports. 35, 9-14.
[155] Pinto, G., Lima, L., Pedra, T., Assumpção, A., Morgado, S., Mascarenhas, L., (2021). Bloodstream
infection by Saccharomyces cerevisiae in a COVID-19 patient receiving probiotic supplementation in
the ICU in Brazil. Access. Microbiol. 3(8), 000250.
[156] Ventoulis, I., Sarmourli, T., Amoiridou, P., Mantzana, P., Exindari, M., Gioula, G., Vyzantiadis, T. A.,
(2020). Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 patients after receiving
supplementation of Saccharomyces in the ICU. J. Fungi. 6(3), 98.
[157] Santos, J. A., Normando, A. G. N., Silva, R. L. C., Paula, R. M., Cembranel, A. C., Santos-Silva, R.,
Guerra, E. N. S., (2020). Oral mucosal lesions in a COVID-19 patient: New signs or secondary
manifestations? Int. J. Infect. Dis. 97, 326–328.


Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!